Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S; A5380 Study Team. Kim AY, et al. Among authors: luetkemeyer af. Clin Infect Dis. 2025 Jul 30:ciaf305. doi: 10.1093/cid/ciaf305. Online ahead of print. Clin Infect Dis. 2025. PMID: 40736252
"It's Been a Very Liberating Experience": Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Men Who Have Sex With Men.
Perkins R, Fredericksen RJ, Christopoulos KA, Beima-Sofie K, Cohen SE, Dombrowski JC, Dright A, Gardner S, Kohler P, Luetkemeyer AF, Pintye J, Celum C. Perkins R, et al. Among authors: luetkemeyer af. Sex Transm Dis. 2025 Dec 1;52(12):728-733. doi: 10.1097/OLQ.0000000000002220. Epub 2025 Jul 10. Sex Transm Dis. 2025. PMID: 40637301 Clinical Trial.
Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension.
Luetkemeyer AF, Donnell D, Cohen SE, Dombrowski JC, Grabow C, Haser G, Brown C, Cannon C, Malinski C, Perkins R, Nasser M, Lopez C, Suchland RJ, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C. Luetkemeyer AF, et al. Lancet Infect Dis. 2025 Aug;25(8):873-883. doi: 10.1016/S1473-3099(25)00085-4. Epub 2025 Mar 24. Lancet Infect Dis. 2025. PMID: 40147465 Clinical Trial.
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.
Covington N, Luetkemeyer AF, Imperial MZ, Dawson R, Cramer Y, Rosenkranz S, Swindells S, Gelmanova I, Avihingsanon A, Arduino RC, Samaneka W, Dooley KE, Savic R, Podany AT, Haas DW. Covington N, et al. Among authors: luetkemeyer af. Pharmacogenet Genomics. 2025 Jun 1;35(4):140-144. doi: 10.1097/FPC.0000000000000562. Epub 2025 Feb 12. Pharmacogenet Genomics. 2025. PMID: 39960813 Free PMC article.
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl D, Chayakulkeeree M, Mendoza JLA, Elistratova P, Makinde O, Morgan G, Portsmouth S, Uehara T, Smith D, Currier JS. Luetkemeyer AF, et al. Clin Infect Dis. 2025 Jul 18;80(6):1235-1244. doi: 10.1093/cid/ciaf029. Clin Infect Dis. 2025. PMID: 39960062 Free PMC article. Clinical Trial.
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Zhang B, Fong Y, Dang L, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Graciaa DS, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Busch S, Benkeser D, Netzl A, Smith DJ, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Gilbert PB, Follmann D; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Zhang B, et al. Among authors: luetkemeyer af. Nat Commun. 2025 Jan 17;16(1):759. doi: 10.1038/s41467-025-55931-w. Nat Commun. 2025. PMID: 39824819 Free PMC article. Clinical Trial.
Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.
Kim S, Can MH, Agizew TB, Auld AF, Balcells ME, Bjerrum S, Dheda K, Dorman SE, Esmail A, Fielding K, Garcia-Basteiro AL, Hanrahan CF, Kebede W, Kohli M, Luetkemeyer AF, Mita C, Reeve BWP, Silva DR, Sweeney S, Theron G, Trajman A, Vassall A, Warren JL, Yotebieng M, Cohen T, Menzies NA. Kim S, et al. Among authors: luetkemeyer af. PLoS Med. 2025 Jan 13;22(1):e1004502. doi: 10.1371/journal.pmed.1004502. eCollection 2025 Jan. PLoS Med. 2025. PMID: 39804959 Free PMC article.
Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends.
Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, Gandhi M, Havlir DV, Liebi C, Luetkemeyer AF, Nguyen JQ, Roman J, Scott H, Torres TS, Cohen SE. Sankaran M, et al. Among authors: luetkemeyer af. JAMA Intern Med. 2025 Mar 1;185(3):266-272. doi: 10.1001/jamainternmed.2024.7178. JAMA Intern Med. 2025. PMID: 39761052
93 results